Quarter Period Consolidated Statement Of Income

SANTEN PHARMACEUTICAL CO.,LTD. - Filing #7254751

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Quarter period consolidated statement of income
Statement of income
Net sales
188,101,000,000 JPY
195,238,000,000 JPY
Cost of sales
96,587,000,000 JPY
92,062,000,000 JPY
Gross profit (loss)
91,513,000,000 JPY
103,176,000,000 JPY
Selling, general and administrative expenses
Depreciation
6,362,000,000 JPY
7,405,000,000 JPY
Selling, general and administrative expenses
68,105,000,000 JPY
75,164,000,000 JPY
Operating profit (loss)
23,408,000,000 JPY
28,013,000,000 JPY
Non-operating income
Non-operating income
3,426,000,000 JPY
4,279,000,000 JPY
Non-operating expenses
Interest expenses
352,000,000 JPY
222,000,000 JPY
Non-operating expenses
602,000,000 JPY
1,019,000,000 JPY
Ordinary profit (loss)
26,232,000,000 JPY
31,272,000,000 JPY
Extraordinary income
Extraordinary income
814,000,000 JPY
1,915,000,000 JPY
Extraordinary losses
Impairment losses
106,000,000 JPY
JPY
Loss on disaster
39,000,000 JPY
755,000,000 JPY
Extraordinary losses
1,909,000,000 JPY
7,384,000,000 JPY
Profit (loss) before income taxes
25,137,000,000 JPY
25,803,000,000 JPY
Income taxes - current
5,136,000,000 JPY
6,529,000,000 JPY
Income taxes - deferred
2,197,000,000 JPY
595,000,000 JPY
Income taxes
7,333,000,000 JPY
7,123,000,000 JPY
Profit (loss)
JPY
JPY
17,804,000,000 JPY
17,804,000,000 JPY
17,804,000,000 JPY
17,804,000,000 JPY
JPY
18,680,000,000 JPY
JPY
18,680,000,000 JPY
18,680,000,000 JPY
18,680,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.